Tempest Therapeutics, Inc.
General ticker "TPST" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $142.2M (TTM average)
Tempest Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -25.2%.
Estimated limits based on current volatility of 4.1%: low 0.95$, high 1.04$
Factors to consider:
- Total employees count: 17 (-10.5%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Going concern doubt, Need substantial additional funding, Regulatory and compliance, Clinical development may not succeed, Intellectual property risks
- Current price 57.5% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.27$, 8.23$]
- 2026-12-31 to 2027-12-31 estimated range: [1.96$, 6.95$]
Financial Metrics affecting the TPST estimates:
- Positive: with PPE of -0.5 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Negative: negative Operating income
- Positive: 19.19 < Shareholder equity ratio, % of 39.38 <= 42.57
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TPST quotes
Long-term TPST plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $29.16MM | $42.03MM | $26.57MM |
| Operating Income | $-29.16MM | $-42.03MM | $-26.57MM |
| Non-Operating Income | $-0.33MM | $0.18MM | $0.31MM |
| Interest Expense | $1.45MM | $1.32MM | $0.21MM |
| R&D Expense | $17.50MM | $28.48MM | $12.61MM |
| Income(Loss) | $-29.49MM | $-41.84MM | $-26.26MM |
| Net Income(Loss)* | $-29.49MM | $-41.84MM | $-26.26MM |
| Stockholders Equity | $26.77MM | $19.13MM | $6.67MM |
| Assets | $51.60MM | $41.49MM | $16.93MM |
| Operating Cash Flow | $-27.36MM | $-33.03MM | $-26.82MM |
| Capital expenditure | $0.17MM | $0.43MM | $0.00MM |
| Investing Cash Flow | $-0.17MM | $-0.43MM | $0.00MM |
| Financing Cash Flow | $35.60MM | $24.50MM | $4.26MM |
| Earnings Per Share** | $-1.91 | $-1.50 | $-6.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.